Bipolar Disorder Depression, Major Depressive Disorder (MDD)
Conditions
Brief summary
Electroconvulsive therapy (ECT) is the treatment of choice for drug-resistant depression (30% of patients), or when there is a short-term risk to the patient's life. Despite its robust efficacy and rapid onset of action, its use is limited both by the limited range of treatment available and by the cognitive effects sometimes induced. The present study focuses on the links between the efficacy of ECT, its cognitive effects and the formation of new neurons in the hippocampus (hippocampal neurogenesis) associated with this treatment.
Interventions
None listed
Sponsors
Centre Hospitalier St Anne
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Study population: depressed subjects treated with ECT * Male or female over 18 years of age * Hospitalised at the Centre Hospitalier Sainte-Anne * Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria * Indication for ECT treatment * Patient has given informed written consent * Beneficiary of a social security scheme 2. Control population: depressed subjects treated without ECT * Male or female over 18 years of age * Hospitalised at the Centre Hospitalier Sainte-Anne * Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria * Patient who has given informed written consent * Beneficiary of a social security scheme 3. Control population: healthy volunteers * Male or female over 18 years of age * Patient with written informed consent * Beneficiary of a social security scheme
Exclusion criteria
1. Study population: depressed subjects with ECT * Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on a substance other than tobacco * Neurological comorbidity: Parkinson's disease, dementia * ECT treatment in the 6 months prior to inclusion * Compulsory care * Protected adults, persons under court protection measures * Persons deprived of liberty by judicial or administrative decision; * Refusal of consent to ECT treatment * Contraindications to ECT (HTIC, recent history of stroke, severe uncontrolled arterial hypertension, contraindication to anaesthesia) * Contraindications to MRI (patients with metal prostheses, claustrophobia) * Pregnant or breast-feeding women 2. Control population: depressed subjects without ECT * Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on any substance other than tobacco * Neurological comorbidity: Parkinson's disease, dementia * ECT treatment in the 6 months prior to inclusion * Compulsory care * Protected adults, persons under court protection measures * Persons deprived of liberty by judicial or administrative decision; * Pregnant or breast-feeding women 3. Control population: healthyvolunteers * Protected adults, persons under legal protection, * Persons deprived of their liberty by judicial or administrative decision ; * persons hospitalised for purposes other than research * Clear psychiatric history * Dependence on any substance other than tobacco * Neurological history: Parkinson's disease, dementia * Pregnant or breast-feeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between increased hippocampal volume and post-ECT retrograde amnesia | After a course of ECT, up to 3 months |
Countries
France
Outcome results
None listed